Skip to main content
    G

    Geron Corporation (GERN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.94
    -0.03 (-2.60%)

    Market Cap: $622.98M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Geron Corporation (GERN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Geron are Prothena Corporation (PRTA), Neurogene (NGNE) and Gyre Therapeutics (GYRE). By market cap, Geron ranks 6th of the 13 companies on this page; Corvus Pharmaceuticals (CRVS) is the largest at $897.52M.

    Peer Comparison

    GERN's ROIC of -7.4% is above the peer median of -14.9%, and its revenue growth of 27.4% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Geron (GERN)$622.98MN/A2.9x-22.0%-7.4%27.4%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    PepGen Ltd (PEPG)$410.98MN/AN/A0.0%N/A0.0%0.00%
    Corvus Pharmaceuticals Inc (CRVS)$897.52MN/AN/A0.0%N/A0.0%0.00%
    Oric Pharmaceuticals Inc (ORIC)$814.71MN/AN/A0.0%N/A0.0%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Entera Bio Ltd (ENTX)$541.57MN/AN/A0.0%-8.5%-100.0%0.00%
    Rigel Pharmaceuticals Inc (RIGL)$837.18M14.2x2.8x106.6%16.7%16.5%0.00%
    Ginkgo Bioworks Holdings (DNA)$622.97MN/A6.1x-192.0%N/A-5.7%0.00%
    Kura Oncology Inc (KURA)$713.90MN/A8.0x0.0%-1125.3%10.1%0.00%
    Peer median$582.27M14.2x5.0x0.0%-14.9%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Geron, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors
    PepGen Ltd (PEPG)
    PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious...
    PEPG competitors
    Corvus Pharmaceuticals Inc (CRVS)
    Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
    CRVS competitors
    Oric Pharmaceuticals Inc (ORIC)
    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers.
    ORIC competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Entera Bio Ltd (ENTX)
    Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies...
    ENTX competitors
    Rigel Pharmaceuticals Inc (RIGL)
    Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases.
    RIGL competitors
    Ginkgo Bioworks Holdings (DNA)
    Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms...
    DNA competitors
    Kura Oncology Inc (KURA)
    Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States.
    KURA competitors

    Frequently Asked Questions About GERN

    Who are Geron's main competitors?

    The companies most similar to Geron include Prothena Corporation (PRTA), Neurogene (NGNE), Gyre Therapeutics (GYRE), PepGen (PEPG) and Corvus Pharmaceuticals (CRVS), listed from the closest match.

    Who is Geron's biggest competitor?

    Corvus Pharmaceuticals (CRVS) is the largest of the similar companies at $897.52M; Prothena Corporation (PRTA) is the closest match by business profile, size, sector and industry.

    How does GERN stock compare with its competitors?

    GERN's P/S is 2.9x against a peer median of 5.0x; its net margin is -22.0% against a peer median of 0.0%.

    Which of Geron's competitors pays a higher dividend?

    Geron pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Geron bigger than its competitors?

    No. Geron is 6th by market cap among the 13 companies on this page; the largest is Corvus Pharmaceuticals (CRVS) at $897.52M.